← All trials
NCT06343402
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2024
- Primary completion
- Aug 31, 2027
- Completion date
- Feb 29, 2028
- First posted
- Apr 2, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 229
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bridge BioResearch Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.